Cancer is one of the leading causes of death for children and young adults. But paradoxically cancer is primarily a disease for older generations. Roughly 2% of new cancers each year are pediatric cases, but the severity of the disease is usually higher. However, although characterized as cancer, pediatric cases often have cellular & molecular properties unique to childhood diseases. A good example is cancer-associated PIK3CA mutations, that when occurring during fetal development results in PIK3CA-related overgrown spectrum. The nature of these arising during embryonic development allows for a unique phenotype in pediatric cases.
Management of pediatric cancer patients has benefited from the use of molecular approaches in the care pathway. Molecular signalling analysis is now included in diagnosis, the identification of patient subgroups, selecting targeted therapies for particular patients, the pharmacological effects of toxicity on patients, and clinical management of pediatric cases currently undergoing treatment. Studies of pediatric oncology signaling have contributed to this in many ways. Therefore, improving our understanding of the molecular pathways that are frequently altered in child malignancies can lead to better diagnosis, treatment and management in pediatric oncology
This Research Topic focuses on the role of molecular signalling in pediatric cancer and how certain mutations will create different outcomes when compared to similar changes in adult cells. We aim to cover how the signalling pathway can be studied and utilized in the treatment of pediatric diseases, which will help improve our understanding of these specific forms of cancer.
In this Research Topic, we welcome: Original Research & Reviews focusing on the characteristics of molecular signaling in pediatric cancer and invite authors to submit their research focusing on the role this plays in the diagnosis, treatment and management of pediatric cancers.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Cancer is one of the leading causes of death for children and young adults. But paradoxically cancer is primarily a disease for older generations. Roughly 2% of new cancers each year are pediatric cases, but the severity of the disease is usually higher. However, although characterized as cancer, pediatric cases often have cellular & molecular properties unique to childhood diseases. A good example is cancer-associated PIK3CA mutations, that when occurring during fetal development results in PIK3CA-related overgrown spectrum. The nature of these arising during embryonic development allows for a unique phenotype in pediatric cases.
Management of pediatric cancer patients has benefited from the use of molecular approaches in the care pathway. Molecular signalling analysis is now included in diagnosis, the identification of patient subgroups, selecting targeted therapies for particular patients, the pharmacological effects of toxicity on patients, and clinical management of pediatric cases currently undergoing treatment. Studies of pediatric oncology signaling have contributed to this in many ways. Therefore, improving our understanding of the molecular pathways that are frequently altered in child malignancies can lead to better diagnosis, treatment and management in pediatric oncology
This Research Topic focuses on the role of molecular signalling in pediatric cancer and how certain mutations will create different outcomes when compared to similar changes in adult cells. We aim to cover how the signalling pathway can be studied and utilized in the treatment of pediatric diseases, which will help improve our understanding of these specific forms of cancer.
In this Research Topic, we welcome: Original Research & Reviews focusing on the characteristics of molecular signaling in pediatric cancer and invite authors to submit their research focusing on the role this plays in the diagnosis, treatment and management of pediatric cancers.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
